US8101861065 - Common Stock

Overall **SMG** gets a fundamental rating of **4** out of 10. We evaluated **SMG** against 84 industry peers in the **Chemicals** industry. **SMG** scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. **SMG** has a valuation in line with the averages, but it does not seem to be growing.

The reported net income has been mixed in the past 5 years: **SMG** reported negative net income in multiple years.

Of the past 5 years **SMG** 4 years had a positive operating cash flow.

The **Return On Invested Capital** of **SMG** (**10.25%**) is better than **89.29%** of its industry peers.

The **Average Return On Invested Capital** over the past 3 years for **SMG** is significantly above the industry average of **6.33%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -7.43% | ||

ROE | N/A | ||

ROIC | 10.25% |

ROA(3y)-3.55%

ROA(5y)3.21%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)11.63%

ROIC(5y)13.61%

Looking at the **Gross Margin**, with a value of **26.01%**, **SMG** is in line with its industry, outperforming **48.81%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 9.74% | ||

PM (TTM) | N/A | ||

GM | 26.01% |

OM growth 3Y-17.38%

OM growth 5Y-8.49%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-10.39%

GM growth 5Y-6.51%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **SMG** is still creating some value.

Compared to 1 year ago, **SMG** has more shares outstanding

An Altman-Z score of **2.46** indicates that **SMG** is not a great score, but indicates only limited risk for bankruptcy at the moment.

Looking at the **Altman-Z score**, with a value of **2.46**, **SMG** is in the better half of the industry, outperforming **67.86%** of the companies in the same industry.

The **Debt to FCF ratio** of **SMG** (**2.49**) is better than **85.71%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | 2.49 | ||

Altman-Z | 2.46 |

ROIC/WACC1.38

WACC7.42%

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.8 | ||

Quick Ratio | 1.09 |

The earnings per share for **SMG** have decreased by **-5.82%** in the last year.

The earnings per share for **SMG** have been decreasing by **-20.79%** on average. This is quite bad

Looking at the last year, **SMG** shows a decrease in **Revenue**. The Revenue has decreased by **-4.30%** in the last year.

The **Revenue** has been growing slightly by **5.92%** on average over the past years.

EPS 1Y (TTM)-5.82%

EPS 3Y-45.69%

EPS 5Y-20.79%

EPS Q2Q%97.44%

Revenue 1Y (TTM)-4.3%

Revenue growth 3Y-4.92%

Revenue growth 5Y5.92%

Sales Q2Q%7.46%

Based on estimates for the next years, **SMG** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **42.72%** on average per year.

Based on estimates for the next years, **SMG** will show a small growth in **Revenue**. The Revenue will grow by **3.42%** on average per year.

EPS Next Y135.47%

EPS Next 2Y80.7%

EPS Next 3Y62.32%

EPS Next 5Y42.72%

Revenue Next Year0.93%

Revenue Next 2Y1.44%

Revenue Next 3Y1.96%

Revenue Next 5Y3.42%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The **Price/Earnings** ratio is **39.62**, which means the current valuation is very expensive for **SMG**.

Compared to an average S&P500 **Price/Earnings** ratio of **30.71**, **SMG** is valued a bit more expensive.

A **Price/Forward Earnings** ratio of **18.62** indicates a rather expensive valuation of **SMG**.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **SMG** is on the same level as its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 39.62 | ||

Fwd PE | 18.62 |

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **SMG** indicates a rather cheap valuation: **SMG** is cheaper than 96.43% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 4.02 | ||

EV/EBITDA | 14.64 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as **SMG**'s earnings are expected to grow with **62.32%** in the coming years.

PEG (NY)0.29

PEG (5Y)N/A

EPS Next 2Y80.7%

EPS Next 3Y62.32%

With a **Yearly Dividend Yield** of **3.97%**, **SMG** has a reasonable but not impressive dividend return.

Compared to an average industry **Dividend Yield** of **3.01**, **SMG** pays a better dividend. On top of this **SMG** pays more dividend than 85.71% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.97% |

The dividend of **SMG** has a limited annual growth rate of **4.70%**.

Dividend Growth(5Y)4.7%

Div Incr Years0

Div Non Decr Years2

DP-58.16%

EPS Next 2Y80.7%

EPS Next 3Y62.32%

**SCOTTS MIRACLE-GRO CO**

NYSE:SMG (9/16/2024, 8:04:00 PM)

After market: 70.52 0 (0%)**70.52**

**+0.78 (+1.12%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.01B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.97% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 39.62 | ||

Fwd PE | 18.62 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.29

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -7.43% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 9.74% | ||

PM (TTM) | N/A | ||

GM | 26.01% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.01

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.8 | ||

Quick Ratio | 1.09 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-5.82%

EPS 3Y-45.69%

EPS 5Y

EPS Q2Q%

EPS Next Y135.47%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-4.3%

Revenue growth 3Y-4.92%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y